Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma models.

While a direct co-treatment of 100 nM trametinib and varying concentrations of navitoclax or A - 1331852 (both BCL-XLi) gave IC 50 similar to each BCL-XLi alone, pre-treatment with 100 nM trametinib for 24 h increased IC50 of each BCL-XLi significantly in one model (DKFZ-BT317) and with a trend towards significance in the second model (DKFZ-BT66) (Fig. 1e , supplementary Fig. 1e and supplementary Table 5 ).

also in 2,760 other papers